RESEARCH GRANT AWARDS
AWARDS LIST.
Totals by Year
2025 - $1,019,994
2024 - 1,139,000
2023 - $891,364
2022 - $1,199,966
2021 - $749,812
2020 - $630,000
2019 - $690,000
2018 - $750,000
2017 - $747,772
2016 - $720,000
2015 - $840,000
2014 - $810,000
2013 - $808,500
2012 - $720,000
2011 - $599,780
2010 - $438,000
2009 - $435,000
2008 - $619,993
2007 - $232,600
2006 - $384,551
Amounts flagged (*) below are funded by Cancer League of Colorado and a generous matching grant from MDC/Richmond American Homes Foundation
Rui Zhao, PhD Quinghong Zhang, PhD
Inhibiting the transcriptional co-repressor CtBP for cancer therapy using cell penetrating peptide
60,000
2012
Jingshi Shen, PhD
Dissection of the perforin pathway in cancer immunotherapy
30,000
2012
Colin Moore, MD
Evaluating the Role of miR 193b in Ewing Sarcoma growth Suppression
30,000
2012
Caroline Kulesza, PhD
Virus Manipulation of a Cellular Chromatin Modifying Complex
30,000
2012
Jordan Jacobelli, PhD
Regulation of lymphoma dissemination by the actin-myosin cytoskeleton
30,000
2012
Amanda Guth, DVM, PhD
Monocyte Blockade with CCR2 Antagonists for Inhibition of tumor metastases
30,000
2012
Robert Doebele, MD, PhD Kurtis D. Davies, PhD
Acquired Resistance to ROS1 inhibition in Non-Small Cell Lung Cancer: Identification of Cellular Mechanisms and Exploration of Alternative Treatment Strategies
30,000
2012
Stephen Malkoski, MD Scott Cramer, PhD
Defining the role of TAK1 in non-small cell lung cancer
60,000
2012
Marileila Varella Garcia, PhD
2012 Cancer Research Summer Fellowship Program
30,000
2012
Antonio Jimeno, MD, PhD Gregory Gan, MD, PhD
Resistance of Human Head and Neck Squamous Cell Carcinoma to Concurrent EGFR and Radiotherapy Mediated Through the Hedgehog Pathway
30,000
2012
Dawn Duval, Ph.D.
Osteosarcoma: Biomarkers of Metastasis and Resistance to Therapy
30,000
2011
James Lambert, Ph.D.
Genome-wide RA interference screen for mediators of cell death induced by a novel vitamin D analog in triple negative breast cancer
30,000
2011
Kim Jihye, Ph.D.
PathCMap Development of pathway signature system for identifying partners of synethetic lethal genes
30,000
2011
Sunshine Axlund, Ph.D.
Tumor initiating and Drug Resistant Properties of a minor Population of Stem-Like Cells in Explant Models of Estrogen Receptor Positive Human Breast Tumors
30,000
2011
Raul Torres, Ph.D.
LPA Regulation of T Cell Tumor Immunity
30,000
2011
Marileila Varella Garcia, Ph.D.
Cancer Research Summer Fellowship Program
30,000
2011
Christopher Porter, M.D. and Jean Mulcahy, M.D.
High Throughput Functional Genetic Screening to Define the Role of Autophagy in Pediatric Brain Tumors
60,000
2011
Henry Thompson, Ph.D. and Barbara Wallner, Ph.D.
Competency Development to Reduce Obesity and Promote Long Term Survival Following treatment for Breast Cancer
59,780
2011
Steve Anderson, Ph.D.
Does cell surface transporter expression determine the response of breast cancer
30,000
2011
Andrew Bradford, Ph.D.
PKCĪ“ as a biomarker and regulator of response to chemotherapy in endometrial cancer
30,000
2011
Rytis Prekeris, Ph.D., and Pepper Schedin, Ph.D.
The regulation of MMP Secretion During the Invasion of Breast Cancer Cells
60,000
2011
Dylan Taatjes, Ph.D.
Identification of transcriptional cofactors that trigger alternations in breast cancer pathology and therapeutic response
30,000
2011
Lindsay Micel, M.D.
Identifying mechanisms of resistance to the novel NAE inhibitor, MLN4924, in melanoma
30,000
2011
Quinghong Zhang, Ph.D.
The Role of CtBP1 in SCC
30,000
2011
Dawn Cochrane, Ph.D.
Restoring miR-200c to aggressive ovarian cancers to attack anoikis resistance
30,000
2011
Pajon, Eduardo, Jr., M.D.
Colorado Cancer Research Clinical Trials Program
30,000
2011
Renee Paulson, Ph.D.
Elucidating the cellular response to hypoxia via functional genomics
30,000
2011